AbbVie Inc. (NYSE:ABBV) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of AbbVie Inc. (NYSE:ABBV) have been given a consensus recommendation of “Moderate Buy” by the thirty analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $272.39.

ABBV has been the subject of several recent analyst reports. Citigroup upped their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Royal Bank Of Canada boosted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a report on Friday, July 10th. Finally, Rothschild & Co Redburn upped their price objective on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong Phase 3 lymphoma results: AbbVie and partner Genmab reported that epcoritamab combined with R-CHOP produced a statistically significant and clinically meaningful improvement in progression-free survival compared with R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The treatment reportedly reduced the risk of disease progression or death by 51%, supporting a potential expansion into frontline treatment and strengthening AbbVie’s oncology pipeline. The companies plan to begin discussions with global regulators. AbbVie and Genmab lymphoma trial announcement
• Positive Sentiment: Parkinson’s drug approval expands growth prospects: AbbVie’s new Parkinson’s pill became the first FDA-approved selective D1/D5 drug, adding a potentially meaningful product to the company’s neuroscience portfolio. AbbVie Parkinson’s drug approval
• Neutral Sentiment: 340B pricing uncertainty: AbbVie joined the federal 340B rebate pilot program ahead of its 2027 launch. Participation could reduce policy uncertainty, but the program may also create additional pricing and rebate pressure, particularly as Vraylar faces a Medicare price cut in 2027. AbbVie 340B rebate pilot
• Negative Sentiment: Reduced 2026 earnings guidance: AbbVie included $216 million of acquired in-process research and development and milestone expenses in its third-quarter outlook. Adjusted EPS guidance is now $3.73–$3.77 for the quarter and $13.76–$13.96 for 2026, down $0.11 from the previous full-year range. The expense is investment-related, but the lower forecast weighs on near-term earnings sentiment. AbbVie updated EPS guidance

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ABBV. State Street Corp boosted its position in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Capital Research Global Investors increased its stake in AbbVie by 0.7% in the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock valued at $5,805,530,000 after acquiring an additional 177,370 shares during the period. Corient Private Wealth LP acquired a new position in AbbVie in the second quarter worth about $559,736,000. Franklin Resources Inc. lifted its position in shares of AbbVie by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock worth $3,400,274,000 after buying an additional 330,104 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Up 1.2%

Shares of AbbVie stock opened at $265.93 on Tuesday. AbbVie has a 12 month low of $190.75 and a 12 month high of $269.39. The stock has a market cap of $469.84 billion, a PE ratio of 75.12, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24. The business has a fifty day simple moving average of $258.05 and a 200-day simple moving average of $235.01.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.